Entrectinib: an orally available, selective tyrosine kinase inhibitor for the treatment of NTRK, ROS1, and ALK fusion-positive solid tumors - Liu, D; Offin, M; Harnicar, S; Li, B T; Drilon, A (Ther Clin Risk Manag, 2018)